{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":44,"searchCount":0},"additional":{"omics_type":["Unknown"],"volume":["6(2)"],"submitter":["Vollmer BL"],"pubmed_abstract":["<h4>Objective</h4>To compare 2-year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS).<h4>Methods</h4>Patients prescribed NTZ, FTY, or DMF at the Rocky Mountain MS Center at University of Colorado were identified. Clinician-reported data were retrospectively collected. Outcomes include a composite effectiveness measure consisting of new T2 lesion, gadolinium-enhancing lesion, and/or clinical relapse, individual effectiveness outcomes and discontinuation over 2 years. Logistic regression was used for data analysis on patients matched by propensity scores and using ATT doubly robust weighting estimator.<h4>Results</h4>A total of 451, 271, and 342 patients were evaluated on NTZ, FTY, and DMF over 2 years, respectively. Patients had a mean age of 39.8 (NTZ), 42.5(FTY), and 45.8 (DMF) years; were predominantly female (76.7% NTZ; 72.0% FTY; 69.6% DMF); and had a mean MS disease duration of 11-12 years for all groups. At ≤24 months, 22.2%, 34.7%, and 33.6% experienced a new T2 lesion, gadolinium-enhancing lesion, and/or clinical relapse on NTZ, FTY, and DMF, respectively. Using ATT doubly robust weighting estimator, FTY versus NTZ and DMF versus NTZ had an odds ratio of 2.00 (95%CI:[1.41-2.85], <i>P</i> < 0.001) and 2.38 [95% CI: 1.68-3.37], <i>P</i> < 0.001) respectively, for experiencing a new T2 lesion, gadolinium enhancing lesion, and/or clinical relapse. At ≤24 months, 32.6%, 34.3%, and 47.1% discontinued NTZ, FTY, and DMF, respectively. The majority of discontinuations were due to becoming JCV positive(12.6%) for NTZ and due to adverse events for both FTY(17%) and DMF(24.0%).<h4>Interpretation</h4>NTZ appears to be more effective and tolerable than FTY and DMF."],"journal":["Annals of clinical and translational neurology"],"pagination":["252-262"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6389745"],"repository":["biostudies-literature"],"pubmed_title":["Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment."],"pmcid":["PMC6389745"],"pubmed_authors":["Vollmer BL","Corboy JR","Nair KV","Sillau S","Alvarez E","Vollmer T"],"view_count":["44"],"additional_accession":[]},"is_claimable":false,"name":"Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.","description":"<h4>Objective</h4>To compare 2-year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS).<h4>Methods</h4>Patients prescribed NTZ, FTY, or DMF at the Rocky Mountain MS Center at University of Colorado were identified. Clinician-reported data were retrospectively collected. Outcomes include a composite effectiveness measure consisting of new T2 lesion, gadolinium-enhancing lesion, and/or clinical relapse, individual effectiveness outcomes and discontinuation over 2 years. Logistic regression was used for data analysis on patients matched by propensity scores and using ATT doubly robust weighting estimator.<h4>Results</h4>A total of 451, 271, and 342 patients were evaluated on NTZ, FTY, and DMF over 2 years, respectively. Patients had a mean age of 39.8 (NTZ), 42.5(FTY), and 45.8 (DMF) years; were predominantly female (76.7% NTZ; 72.0% FTY; 69.6% DMF); and had a mean MS disease duration of 11-12 years for all groups. At ≤24 months, 22.2%, 34.7%, and 33.6% experienced a new T2 lesion, gadolinium-enhancing lesion, and/or clinical relapse on NTZ, FTY, and DMF, respectively. Using ATT doubly robust weighting estimator, FTY versus NTZ and DMF versus NTZ had an odds ratio of 2.00 (95%CI:[1.41-2.85], <i>P</i> < 0.001) and 2.38 [95% CI: 1.68-3.37], <i>P</i> < 0.001) respectively, for experiencing a new T2 lesion, gadolinium enhancing lesion, and/or clinical relapse. At ≤24 months, 32.6%, 34.3%, and 47.1% discontinued NTZ, FTY, and DMF, respectively. The majority of discontinuations were due to becoming JCV positive(12.6%) for NTZ and due to adverse events for both FTY(17%) and DMF(24.0%).<h4>Interpretation</h4>NTZ appears to be more effective and tolerable than FTY and DMF.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Feb","modification":"2024-11-12T15:26:58.034Z","creation":"2019-08-04T08:19:34Z"},"accession":"S-EPMC6389745","cross_references":{"pubmed":["30847358"],"doi":["10.1002/acn3.700"]}}